Sematrinity 4 mg/3 mL Injection is a prescription medication developed by Sun Pharmaceutical Industries in India (launched March 2026) containing the active ingredient semaglutide.It is a GLP-1 receptor agonist designed for the management of type 2 diabetes and sometimes used for weight management, administered as a once-weekly subcutaneous injection .